Diabetes, perioperative ischaemia and volatile anaesthetics: Consequences of derangements in myocardial substrate metabolism

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  van den Brom, Charissa E ^a   Bulte, Carolien S E ^a   Loer, Stephan A ^a   Bouwman, R Arthur ^a   Boer, Christa ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diabetes; Heart; Ischaemia; Substrate metabolism; Volatile anaesthetics

Indexed keywords

BIGUANIDE; CARNITINE PALMITOYLTRANSFERASE I; DESFLURANE; DICHLOROACETIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ETOMOXIR; EXENDIN 4; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE INSULIN POTASSIUM; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; ISOFLURANE; LIRAGLUTIDE; METFORMIN; OXFENICINE; PERHEXILINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PYRUVATE DEHYDROGENASE; RANOLAZINE; ROSIGLITAZONE; SEVOFLURANE; TRIACYLGLYCEROL; TRIMETAZIDINE; UNCLASSIFIED DRUG;

ANESTHESIA; CLINICAL PRACTICE; CORONARY ARTERY BYPASS GRAFT; DISEASE SEVERITY; DRUG HALF LIFE; DRUG SAFETY; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; ESTERIFICATION; EX VIVO STUDY; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLYCOGEN ANALYSIS; GLYCOLYSIS; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE PERFUSION; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; IMMOBILIZATION; IMPAIRED GLUCOSE TOLERANCE; IN VIVO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIOPERATIVE PERIOD; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; REVIEW; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, INHALATION; ANESTHETICS, GENERAL; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PERIOPERATIVE CARE; SUBSTRATE SPECIFICITY;

EID: 84874417337     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-42     Document Type: Review

References (155)

1. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the american college of cardiology/american heart association task force on practice guidelines (writing committee to revise the,guidelines on perioperative cardiovascular evaluation for noncardiac surgery): developed in collaboration with the american society of echocardiography, american society of nuclear cardiology, heart rhythm society, society of cardiovascular anesthesiologists, society for cardiovascular angiography and interventions, society for vascular medicine and biology, and society for vascular surgery. Circulation 2002, 2007(116):e418-e499.
2. Gupta PK, Gupta H, Sundaram A, Kaushik M, Fang X, Miller WJ, Esterbrooks DJ, Hunter CB, Pipinos II, Johanning JM, Lynch TG, Forse RA, Mohiuddin SM, Mooss AN. Development and validation of a risk calculator for prediction of cardiac risk after surgery. Circulation 2011, 124:381-387. 10.1161/CIRCULATIONAHA.110.015701, 21730309.
3. Unwin N, Whiting D, Guariguata L, Hennis A, Husseini A, Ji L, Kissimova-Skarbek K, Libman I, Mayer-Davis E, Motala A, Narayan V, Ramachandran A, Roglic G, Sham J, Wareham N, Zhang P. IDF diabetes atlas 2011 2011, Brussels: International Diabetes Federation, 5.
4. Preis SR, Pencina MJ, Hwang SJ, D'Agostino RB, Savage PJ, Levy D, Fox CS. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham heart study. Circulation 2009, 120:212-220. 10.1161/CIRCULATIONAHA.108.846519, 2789428, 19581493.
5. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE, Pedan A, Goldman L. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999, 100:1043-1049. 10.1161/01.CIR.100.10.1043, 10477528.
6. Frassdorf J, De Hert S, Schlack W. Anaesthesia and myocardial ischaemia/reperfusion injury. Br J Anaesth 2009, 103:89-98. 10.1093/bja/aep141, 19502287.
7. De Hert SG, Preckel B, Hollmann MW, Schlack WS. Drugs mediating myocardial protection. Eur J Anaesthesiol 2009, 26:985-995. 10.1097/EJA.0b013e32832fad8b, 19644380.
8. Huhn R, Heinen A, Hollmann MW, Schlack W, Preckel B, Weber NC. Cyclosporine A administered during reperfusion fails to restore cardioprotection in prediabetic Zucker obese rats in vivo. Nutr Metab Cardiovasc Dis 2010, 20:706-712. 10.1016/j.numecd.2009.06.010, 19819119.
9. Kehl F, Krolikowski JG, Mraovic B, Pagel PS, Warltier DC, Kersten JR. Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction. Anesthesiology 2002, 96:183-188. 10.1097/00000542-200201000-00032, 11753019.
10. Lucchinetti E, Wang L, Ko KW, Troxler H, Hersberger M, Zhang L, Omar MA, Lopaschuk GD, Clanachan AS, Zaugg M. Enhanced glucose uptake via GLUT4 fuels recovery from calcium overload after ischaemia-reperfusion injury in sevoflurane- but not propofol-treated hearts. Br J Anaesth 2011, 106:792-800. 10.1093/bja/aer065, 21474475.
11. Lucchinetti E, Hofer C, Bestmann L, Hersberger M, Feng J, Zhu M, Furrer L, Schaub MC, Tavakoli R, Genoni M, Zollinger A, Zaugg M. Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery: inhalational versus intravenous anesthetics. Anesthesiology 2007, 106:444-457. 10.1097/00000542-200703000-00008, 17325502.
12. Wang L, Ko KW, Lucchinetti E, Zhang L, Troxler H, Hersberger M, Omar MA, Posse de Chaves EI, Lopaschuk GD, Clanachan AS, Zaugg M. Metabolic profiling of hearts exposed to sevoflurane and propofol reveals distinct regulation of fatty acid and glucose oxidation: CD36 and pyruvate dehydrogenase as key regulators in anesthetic-induced fuel shift. Anesthesiology 2010, 113:541-551.
13. Winterstein H. Ueber die Sauerstoffatmung des isolierten Saeugetierherzens. Z Allg Physiol 1904, 4:339-359.
14. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997, 34:25-33. 10.1016/S0008-6363(97)00047-3, 9217869.
15. Carley AN, Severson DL. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 2005, 1734:112-126. 10.1016/j.bbalip.2005.03.005, 15904868.
16. Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 1972, 15:289-329. 10.1016/0033-0620(72)90029-1, 4564017.
17. Taegtmeyer H. Glycogen in the heart-an expanded view. J Mol Cell Cardiol 2004, 37:7-10. 10.1016/j.yjmcc.2004.05.001, 15242730.
18. Shepherd PR, Kahn BB. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med 1999, 341:248-257. 10.1056/NEJM199907223410406, 10413738.
19. Coort SL, Bonen A, van der Vusse GJ, Glatz JF, Luiken JJ. Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: role of sarcolemmal substrate transporters. Mol Cell Biochem 2007, 299:5-18. 10.1007/s11010-005-9030-5, 1915649, 16988889.
20. Lewin TM, Coleman RA. Regulation of myocardial triacylglycerol synthesis and metabolism. Biochim Biophys Acta 2003, 1634:63-75. 10.1016/j.bbalip.2003.09.006, 14643794.
21. Kerner J, Hoppel C. Fatty acid import into mitochondria. Biochim Biophys Acta 2000, 1486:1-17. 10.1016/S1388-1981(00)00044-5, 10856709.
22. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005, 85:1093-1129. 10.1152/physrev.00006.2004, 15987803.
23. Saddik M, Lopaschuk GD. Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 1991, 266:8162-8170.
24. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010, 90:207-258. 10.1152/physrev.00015.2009, 20086077.
25. van den Brom CE, Bosmans JW, Vlasblom R, Handoko ML, Huisman MC, Lubberink M, Molthoff CF, Lammertsma AA, Ouwens DM, Diamant M, Boer C. Diabetic cardiomyopathy in Zucker diabetic fatty rats: the forgotten right ventricle. Cardiovasc Diabetol 2010, 9:25. 10.1186/1475-2840-9-25, 2898761, 20550678.
26. van den Brom CE, Huisman MC, Vlasblom R, Boontje NM, Duijst S, Lubberink M, Molthoff CF, Lammertsma AA, Van der Velden J, Boer C, Ouwens DM, Diamant M. Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovasc Diabetol 2009, 8:39. 10.1186/1475-2840-8-39, 2722582, 19624828.
27. Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD. Targeting fatty acid and carbohydrate oxidation-a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813, 2011:1333-1350.
28. Opie LH. The heart; Physiology and Metabolism 1991, New York: Raven Press, 3589374, 23472207.
29. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974, 34:29-34. 10.1016/0002-9149(74)90089-7, 4835750.
30. Rennert G, Saltz-Rennert H, Wanderman K, Weitzman S. Size of acute myocardial infarcts in patients with diabetes mellitus. Am J Cardiol 1985, 55:1629-1630. 10.1016/0002-9149(85)90988-9, 4003308.
31. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006, 55:466-473. 10.2337/diabetes.55.02.06.db05-1164, 16443782.
32. Paulson DJ. The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 1997, 34:104-112. 10.1016/S0008-6363(97)00018-7, 9217879.
33. van den Brom CE, Bulte CS, Kloeze BM, Loer SA, Boer C, Bouwman RA. High fat diet-induced glucose intolerance impairs myocardial function, but not myocardial perfusion during hyperaemia: a pilot study. Cardiovasc Diabetol 2012, 11:74. 10.1186/1475-2840-11-74, 3458910, 22716959.
34. Ivanova M, Janega P, Matejikova J, Simoncikova P, Pancza D, Ravingerova T, Barancik M. Activation of Akt kinase accompanies increased cardiac resistance to ischemia/reperfusion in rats after short-term feeding with lard-based high-fat diet and increased sucrose intake. Nutr Res 2011, 31:631-643. 10.1016/j.nutres.2011.08.005, 21925349.
35. Rennison JH, McElfresh TA, Chen X, Anand VR, Hoit BD, Hoppel CL, Chandler MP. Prolonged exposure to high dietary lipids is not associated with lipotoxicity in heart failure. J Mol Cell Cardiol 2009, 46:883-890. 10.1016/j.yjmcc.2009.02.019, 2683194, 19265702.
36. Jordan JE, Simandle SA, Tulbert CD, Busija DW, Miller AW. Fructose-fed rats are protected against ischemia/reperfusion injury. J Pharmacol Exp Ther 2003, 307:1007-1011. 10.1124/jpet.103.055970, 14534360.
37. Morgan EE, Rennison JH, Young ME, McElfresh TA, Kung TA, Tserng KY, Hoit BD, Stanley WC, Chandler MP. Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure. Am J Physiol Heart Circ Physiol 2006, 290:H1899-H1904. 10.1152/ajpheart.01014.2005, 16339830.
38. Rennison JH, McElfresh TA, Okere IC, Vazquez EJ, Patel HV, Foster AB, Patel KK, Chen Q, Hoit BD, Tserng KY, Hassan MO, Hoppel CL, Chandler MP. High-fat diet postinfarction enhances mitochondrial function and does not exacerbate left ventricular dysfunction. Am J Physiol Heart Circ Physiol 2007, 292:H1498-H1506.
39. Mozaffari MS, Patel C, Ballas C, Schaffer SW. Effects of excess salt and fat intake on myocardial function and infarct size in rat. Life Sci 2006, 78:1808-1813. 10.1016/j.lfs.2005.08.014, 16257419.
40. Berthiaume JM, Young ME, Chen X, McElfresh TA, Yu X, Chandler MP. Normalizing the metabolic phenotype after myocardial infarction: impact of subchronic high fat feeding. J Mol Cell Cardiol 2012, 53:125-133. 10.1016/j.yjmcc.2012.04.005, 22542451.
41. Song T, Lv LY, Xu J, Tian ZY, Cui WY, Wang QS, Qu G, Shi XM. Diet-induced obesity suppresses sevoflurane preconditioning against myocardial ischemia-reperfusion injury: role of AMP-activated protein kinase pathway. Exp Biol Med (Maywood) 2011, 236:1427-1436.
42. Morel S, Berthonneche C, Tanguy S, Toufektsian MC, Perret P, Ghezzi C, de Leiris J, Boucher F. Early pre-diabetic state alters adaptation of myocardial glucose metabolism during ischemia in rats. Mol Cell Biochem 2005, 272:9-17. 10.1007/s11010-005-4778-1, 16010967.
43. Maddaford TG, Russell JC, Pierce GN. Postischemic cardiac performance in the insulin-resistant JCR:LA-cp rat. Am J Physiol 1997, 273:H1187-H1192.
44. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes 2002, 51:1110-1117. 10.2337/diabetes.51.4.1110, 11916933.
45. Mozaffari MS, Schaffer SW. Myocardial ischemic-reperfusion injury in a rat model of metabolic syndrome. Obesity (Silver Spring) 2008, 16:2253-2258.
46. Thakker GD, Frangogiannis NG, Zymek PT, Sharma S, Raya JL, Barger PM, Taegtmeyer H, Entman ML, Ballantyne CM. Increased myocardial susceptibility to repetitive ischemia with high-fat diet-induced obesity. Obesity (Silver Spring) 2008, 16:2593-2600.
47. Aasum E, Hafstad AD, Severson DL, Larsen TS. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 2003, 52:434-441.
48. Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, Jucker BM. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005, 54:554-562.
49. Wang P, Chatham JC. Onset of diabetes in Zucker diabetic fatty (ZDF) rats leads to improved recovery of function after ischemia in the isolated perfused heart. Am J Physiol Endocrinol Metab 2004, 286:E725-E736. 10.1152/ajpendo.00295.2003, 14722022.
50. Hoshida S, Yamashita N, Otsu K, Kuzuya T, Hori M. Cholesterol feeding exacerbates myocardial injury in Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 2000, 278:H256-H262.
51. Higuchi M, Miyagi K, Nakasone J, Sakanashi M. Role of high glycogen in underperfused diabetic rat hearts with added norepinephrine. J Cardiovasc Pharmacol 1995, 26:899-907. 10.1097/00005344-199512000-00008, 8606526.
52. Cross HR, Opie LH, Radda GK, Clarke K. Is a high glycogen content beneficial or detrimental to the ischemic rat heart? A controversy resolved. Circ Res 1996, 78:482-491. 10.1161/01.RES.78.3.482, 8593707.
53. Feuvray D, Lopaschuk GD. Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovasc Res 1997, 34:113-120. 10.1016/S0008-6363(97)00037-0, 9217880.
54. Yao YT, Fang NX, Shi CX, Li LH. Sevoflurane postconditioning protects isolated rat hearts against ischemia-reperfusion injury. Chin Med J (Engl) 2010, 123:1320-1328.
55. Bouwman RA, Vreden MJ, Hamdani N, Wassenaar LE, Smeding L, Loer SA, Stienen GJ, Lamberts RR. Effect of bupivacaine on sevoflurane-induced preconditioning in isolated rat hearts. Eur J Pharmacol 2010, 647:132-138. 10.1016/j.ejphar.2010.08.014, 20816812.
56. Tosaka S, Tosaka R, Matsumoto S, Maekawa T, Cho S, Sumikawa K. Roles of cyclooxygenase 2 in sevoflurane- and olprinone-induced early phase of preconditioning and postconditioning against myocardial infarction in rat hearts. J Cardiovasc Pharmacol Ther 2011, 16:72-78. 10.1177/1074248410380208, 20938040.
57. Obal D, Dettwiler S, Favoccia C, Scharbatke H, Preckel B, Schlack W. The influence of mitochondrial KATP-channels in the cardioprotection of preconditioning and postconditioning by sevoflurane in the rat in vivo. Anesth Analg 2005, 101:1252-1260. 10.1213/01.ANE.0000181336.96511.32, 16243977.
58. Lang XE, Wang X, Jin JH. Mechanisms of cardioprotection by isoflurane against I/R injury. Front Biosci 2013, 18:387-393. 10.2741/4109, 23276931.
59. Yao Y, Li L, Li L, Gao C, Shi C. Sevoflurane postconditioning protects chronically-infarcted rat hearts against ischemia-reperfusion injury by activation of pro-survival kinases and inhibition of mitochondrial permeability transition pore opening upon reperfusion. Biol Pharm Bull 2009, 32:1854-1861. 10.1248/bpb.32.1854, 19881297.
60. Stadnicka A, Marinovic J, Ljubkovic M, Bienengraeber MW, Bosnjak ZJ. Volatile anesthetic-induced cardiac preconditioning. J Anesth 2007, 21:212-219. 10.1007/s00540-006-0486-6, 17458651.
61. Lattermann R, Schricker T, Wachter U, Georgieff M, Goertz A. Understanding the mechanisms by which isoflurane modifies the hyperglycemic response to surgery. Anesth Analg 2001, 93:121-127.
62. Bouwman RA, Musters RJ, van Beek-Harmsen BJ, de Lange JJ, Boer C. Reactive oxygen species precede protein kinase C-delta activation independent of adenosine triphosphate-sensitive mitochondrial channel opening in sevoflurane-induced cardioprotection. Anesthesiology 2004, 100:506-514. 10.1097/00000542-200403000-00008, 15108962.
63. Costa AD, Quinlan CL, Andrukhiv A, West IC, Jaburek M, Garlid KD. The direct physiological effects of mitoK(ATP) opening on heart mitochondria. Am J Physiol Heart Circ Physiol 2006, 290:H406-H415.
64. Flores JE, McFarland LM, Vanderbilt A, Ogasawara AK, Williams SP. The effects of anesthetic agent and carrier gas on blood glucose and tissue uptake in mice undergoing dynamic FDG-PET imaging: sevoflurane and isoflurane compared in air and in oxygen. Mol Imaging Biol 2008, 10:192-200. 10.1007/s11307-008-0137-4, 18516648.
65. Toyama H, Ichise M, Liow JS, Vines DC, Seneca NM, Modell KJ, Seidel J, Green MV, Innis RB. Evaluation of anesthesia effects on [18 F]FDG uptake in mouse brain and heart using small animal PET. Nucl Med Biol 2004, 31:251-256. 10.1016/S0969-8051(03)00124-0, 15013491.
66. Kudoh A, Katagai H, Takazawa T. Sevoflurane increases glucose transport in skeletal muscle cells. Anesth Analg 2002, 95:123-128. table, 10.1097/00000539-200207000-00022, 12088955.
67. Ewart RB, Rusy BF, Bradford MW. Effects of enflurane on release of insulin by pancreatic islets in vitro. Anesth Analg 1981, 60:878-884.
68. Tanaka K, Kawano T, Tsutsumi YM, Kinoshita M, Kakuta N, Hirose K, Kimura M, Oshita S. Differential effects of propofol and isoflurane on glucose utilization and insulin secretion. Life Sci 2011, 88:96-103. 10.1016/j.lfs.2010.10.032, 21056586.
69. Zuurbier CJ, Keijzers PJ, Koeman A, Van Wezel HB, Hollmann MW. Anesthesia's effects on plasma glucose and insulin and cardiac hexokinase at similar hemodynamics and without major surgical stress in fed rats. Anesth Analg 2008, 106:135-142. 10.1213/01.ane.0000297299.91527.74, 18165568.
70. Kitamura T, Ogawa M, Kawamura G, Sato K, Yamada Y. The effects of sevoflurane and propofol on glucose metabolism under aerobic conditions in fed rats. Anesth Analg 2009, 109:1479-1485. 10.1213/ANE.0b013e3181b8554a, 19843785.
71. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, Krumholz HM. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 2005, 111:3078-3086. 10.1161/CIRCULATIONAHA.104.517839, 15939812.
72. Katakam PV, Jordan JE, Snipes JA, Tulbert CD, Miller AW, Busija DW. Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance. Am J Physiol Regul Integr Comp Physiol 2007, 292:R920-R926.
73. Wagner C, Kloeting I, Strasser RH, Weinbrenner C. Cardioprotection by postconditioning is lost in WOKW rats with metabolic syndrome: role of glycogen synthase kinase 3beta. J Cardiovasc Pharmacol 2008, 52:430-437. 10.1097/FJC.0b013e31818c12a7, 19033822.
74. Ferdinandy P, Szilvassy Z, Horvath LI, Csont T, Csonka C, Nagy E, Szentgyorgyi R, Nagy I, Koltai M, Dux L. Loss of pacing-induced preconditioning in rat hearts: role of nitric oxide and cholesterol-enriched diet. J Mol Cell Cardiol 1997, 29:3321-3333. 10.1006/jmcc.1997.0557, 9441838.
75. Kocic I, Konstanski Z, Kaminski M, Dworakowska D, Dworakowski R. Experimental hyperlipidemia prevents the protective effect of ischemic preconditioning on the contractility and responsiveness to phenylephrine of rat-isolated stunned papillary muscle. Gen Pharmacol 1999, 33:213-219. 10.1016/S0306-3623(99)00017-8, 10480653.
76. Zhang FJ, Ma LL, Wang WN, Qian LB, Yang MJ, Yu J, Chen G, Yu LN, Yan M. Hypercholesterolemia abrogates sevoflurane-induced delayed preconditioning against myocardial infarct in rats by alteration of nitric oxide synthase signaling. Shock 2012, 37:485-491. 10.1097/SHK.0b013e318249b7b6, 22266969.
77. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Circulation 1999, 99:2626-2632. 10.1161/01.CIR.99.20.2626, 10338454.
78. Weber NC, Goletz C, Huhn R, Grueber Y, Preckel B, Schlack W, Ebel D. Blockade of anaesthetic-induced preconditioning in the hyperglycaemic myocardium: the regulation of different mitogen-activated protein kinases. Eur J Pharmacol 2008, 592:48-54. 10.1016/j.ejphar.2008.07.010, 18655783.
79. Kehl F, Krolikowski JG, Weihrauch D, Pagel PS, Warltier DC, Kersten JR. N-acetylcysteine restores isoflurane-induced preconditioning against myocardial infarction during hyperglycemia. Anesthesiology 2003, 98:1384-1390. 10.1097/00000542-200306000-00013, 12766647.
80. Huhn R, Heinen A, Weber NC, Hollmann MW, Schlack W, Preckel B. Hyperglycaemia blocks sevoflurane-induced postconditioning in the rat heart in vivo: cardioprotection can be restored by blocking the mitochondrial permeability transition pore. Br J Anaesth 2008, 100:465-471. 10.1093/bja/aen022, 18305078.
81. Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 2000, 278:H1218-H1224.
82. Tanaka K, Kehl F, Gu W, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR. Isoflurane-induced preconditioning is attenuated by diabetes. Am J Physiol Heart Circ Physiol 2002, 282:H2018-H2023.
83. Raphael J, Gozal Y, Navot N, Zuo Z. Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase/Akt and endothelial nitric oxide synthase signaling. J Cardiovasc Pharmacol 2010, 55:348-357. 10.1097/FJC.0b013e3181d26583, 20125034.
84. Kristiansen SB, Lofgren B, Stottrup NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT, Botker HE, Flyvbjerg A. Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 2004, 47:1716-1721. 10.1007/s00125-004-1514-4, 15480537.
85. Miki T, Itoh T, Sunaga D, Miura T. Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol 2012, 11:67. 10.1186/1475-2840-11-67, 3461466, 22694800.
86. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 2005, 54:2360-2364. 10.2337/diabetes.54.8.2360, 16046302.
87. Drenger B, Ostrovsky IA, Barak M, Nechemia-Arbely Y, Ziv E, Axelrod JH. Diabetes blockade of sevoflurane postconditioning is Not restored by insulin in the Rat heart: phosphorylated signal transducer and activator of transcription 3- and phosphatidylinositol 3-kinase-mediated inhibition. Anesthesiology 2011, 114:1364-1372. 10.1097/ALN.0b013e31820efafd, 21368653.
88. Paiva MA, Rutter-Locher Z, Goncalves LM, Providencia LA, Davidson SM, Yellon DM, Mocanu MM. Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am J Physiol Heart Circ Physiol 2011, 300:H2123-H2134. 10.1152/ajpheart.00707.2010, 3119096, 21421816.
89. Penna C, Mancardi D, Gattullo D, Pagliaro P. Myocardial protection from ischemic preconditioning is not blocked by sub-chronic inhibition of carnitine palmitoyltransferase I. Life Sci 2005, 77:2004-2017. 10.1016/j.lfs.2005.03.017, 15919095.
90. Lopaschuk GD, Spafford MA, Davies NJ, Wall SR. Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia. Circ Res 1990, 66:546-553. 10.1161/01.RES.66.2.546, 2297817.
91. Lopaschuk GD, Saddik M. The relative contribution of glucose and fatty acids to ATP production in hearts reperfused following ischemia. Mol Cell Biochem 1992, 116:111-116. 10.1007/BF01270577, 1480139.
92. Kennedy JA, Kiosoglous AJ, Murphy GA, Pelle MA, Horowitz JD. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol 2000, 36:794-801. 10.1097/00005344-200012000-00016, 11117381.
93. Molaparast-Saless F, Liedtke AJ, Nellis SH. Effects of the fatty acid blocking agents, oxfenicine and 4-bromocrotonic acid, on performance in aerobic and ischemic myocardium. J Mol Cell Cardiol 1987, 19:509-520. 10.1016/S0022-2828(87)80402-9, 3625784.
94. Kara AF, Demiryurek S, Celik A, Tarakcioglu M, Demiryurek AT. Effects of trimetazidine on myocardial preconditioning in anesthetized rats. Eur J Pharmacol 2004, 503:135-145. 10.1016/j.ejphar.2004.09.037, 15496308.
95. Mouquet F, Rousseau D, Domergue-Dupont V, Grynberg A, Liao R. Effects of trimetazidine, a partial inhibitor of fatty acid oxidation, on ventricular function and survival after myocardial infarction and reperfusion in the rat. Fundam Clin Pharmacol 2010, 24:469-476.
96. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996, 93:135-142. 10.1161/01.CIR.93.1.135, 8616920.
97. Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther 2007, 321:213-220. 10.1124/jpet.106.115519, 17202401.
98. McVeigh JJ, Lopaschuk GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 1990, 259:H1079-H1085.
99. Lopaschuk GD, McNeil GF, McVeigh JJ. Glucose oxidation is stimulated in reperfused ischemic hearts with the carnitine palmitoyltransferase 1 inhibitor, Etomoxir. Mol Cell Biochem 1989, 88:175-179.
100. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan R, Isea JE, Romero G. Metabolic modulation of acute myocardial infarction. The ECLA (estudios cardiologicos latinoamerica) collaborative group. Circulation 1998, 98:2227-2234. 10.1161/01.CIR.98.21.2227, 9867443.
101. Di MS, Boldrini B, Conti U, Marcucci G, Morgantini E, Ferrannini C, Natali A. Effects of GIK (glucose-insulin-potassium) on stress-induced myocardial ischaemia. Clin Sci (Lond) 2010, 119:37-44.
102. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI study group. Diabetes insulin-glucose in acute myocardial infarction. Eur Heart J 1996, 17:1337-1344. 10.1093/oxfordjournals.eurheartj.a015067, 8880018.
103. Jonassen AK, Aasum E, Riemersma RA, Mjos OD, Larsen TS. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther 2000, 14:615-623. 10.1023/A:1007802630604, 11300362.
104. Ceremuzynski L, Budaj A, Czepiel A, Burzykowski T, Achremczyk P, Smielak-Korombel W, Maciejewicz J, Dziubinska J, Nartowicz E, Kawka-Urbanek T, Piotrowski W, Hanzlik J, Cieslinski A, Kawecka-Jaszcz K, Gessek J, Wrabec K. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther 1999, 13:191-200. 10.1023/A:1007787924085, 10439881.
105. van der Horst IC, Zijlstra F, van 't Hof CJ, Doggen AW, de Boer MJ, Suryapranata H, Hoorntje JC, Dambrink JH, Gans RO, Bilo HJ. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 2003, 42:784-791. 10.1016/S0735-1097(03)00830-1, 12957421.
106. Thomas DJ, Platt HS, Alberti KG. Insulin infusion (GIK) in the treatment of type 2 (non-insulin dependent) diabetes during the perioperative period. Br J Surg 1986, 73:898-901. 10.1002/bjs.1800731116, 3790919.
107. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004, 109:1497-1502. 10.1161/01.CIR.0000121747.71054.79, 15006999.
108. Doenst T, Richwine RT, Bray MS, Goodwin GW, Frazier OH, Taegtmeyer H. Insulin improves functional and metabolic recovery of reperfused working rat heart. Ann Thorac Surg 1999, 67:1682-1688. 10.1016/S0003-4975(99)00326-4, 10391275.
109. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001, 89:1191-1198. 10.1161/hh2401.101385, 11739285.
110. Nygren JO, Thorell A, Soop M, Efendic S, Brismar K, Karpe F, Nair KS, Ljungqvist O. Perioperative insulin and glucose infusion maintains normal insulin sensitivity after surgery. Am J Physiol 1998, 275:E140-E148.
111. Sato H, Carvalho G, Sato T, Bracco D, Codere-Maruyama T, Lattermann R, Hatzakorzian R, Matsukawa T, Schricker T. Perioperative tight glucose control with hyperinsulinemic-normoglycemic clamp technique in cardiac surgery. Nutrition 2010, 26:1122-1129. 10.1016/j.nut.2009.10.005, 20097532.
112. Carvalho G, Moore A, Qizilbash B, Lachapelle K, Schricker T. Maintenance of normoglycemia during cardiac surgery. Anesth Analg 2004, 99:319-324. table.
113. Zuurbier CJ, Hoek FJ, Van Dijk J, Abeling NG, Meijers JC, Levels JH, De Jonge E, de Mol BA, Van Wezel HB. Perioperative hyperinsulinaemic normoglycaemic clamp causes hypolipidaemia after coronary artery surgery. Br J Anaesth 2008, 100:442-450. 10.1093/bja/aen018, 18305079.
114. Forlani S, Tomai F, De Paulis R, Turani F, Colella DF, Nardi P, De Notaris S, Moscarelli M, Magliano G, Crea F, Chiariello L. Preoperative shift from glibenclamide to insulin is cardioprotective in diabetic patients undergoing coronary artery bypass surgery. J Cardiovasc Surg (Torino) 2004, 45:117-122.
115. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002, 16:1027-1040. 10.1096/fj.01-0793com, 12087064.
116. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns-Kurtis CL, Mirabile RC, Aravindhan K, Ohlstein EH. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 2003, 108:2393-2399. 10.1161/01.CIR.0000093187.42015.6C, 14557369.
117. Bulhak AA, Jung C, Ostenson CG, Lundberg JO, Sjoquist PO, Pernow J. PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway. Am J Physiol Heart Circ Physiol 2009, 296:H719-H727. 10.1152/ajpheart.00394.2008, 19151258.
118. Lucchinetti E, Aguirre J, Feng J, Zhu M, Suter M, Spahn DR, Harter L, Zaugg M. Molecular evidence of late preconditioning after sevoflurane inhalation in healthy volunteers. Anesth Analg 2007, 105:629-640. 10.1213/01.ane.0000278159.88636.aa, 17717216.
119. Yue TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2001, 104:2588-2594. 10.1161/hc4601.099403, 11714655.
120. Ito H, Nakano A, Kinoshita M, Matsumori A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 2003, 83:1715-1721. 10.1097/01.LAB.0000106724.29121.DA, 14691289.
121. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002, 51:1507-1514. 10.2337/diabetes.51.5.1507, 11978649.
122. Shoghi KI, Finck BN, Schechtman KB, Sharp T, Herrero P, Gropler RJ, Welch MJ. In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy. Circ Cardiovasc Imaging 2009, 2:373-381. 10.1161/CIRCIMAGING.108.843227, 2760020, 19808625.
123. Lotz C, Lange M, Redel A, Stumpner J, Schmidt J, Tischer-Zeitz T, Roewer N, Kehl F. Peroxisome-proliferator-activated receptor gamma mediates the second window of anaesthetic-induced preconditioning. Exp Physiol 2011, 96:317-324. 10.1113/expphysiol.2010.055590, 21123361.
124. Russell RR, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ, Young LH. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004, 114:495-503. 503766, 15314686.
125. Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R, Lefer DJ. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008, 57:696-705. 10.2337/db07-1098, 18083782.
126. Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Sillje HH, de Boer RA. Metformin improves cardiac function in a non-diabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol 2011,
127. Paiva MA, Goncalves LM, Providencia LA, Davidson SM, Yellon DM, Mocanu MM. Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction. Cardiovasc Drugs Ther 2010, 24:25-32. 10.1007/s10557-010-6222-3, 2874156, 20229055.
128. Lavanchy N, Christe G, Cand F, Wiernsperger N, Verdetti J. Effects of chronic treatment with glibenclamide and/or metformin on the resistance to ischaemia of isolated hearts from Zucker diabetic fatty rats (ZDF/GMI-fa/fa). Br J Diabetes Vasc Dis 2003, 3:375-380.
129. Lamberts RR, Onderwater G, Hamdani N, Vreden MJ, Steenhuisen J, Eringa EC, Loer SA, Stienen GJ, Bouwman RA. Reactive oxygen species-induced stimulation of 5'AMP-activated protein kinase mediates sevoflurane-induced cardioprotection. Circulation 2009, 120:S10-S15. 10.1161/CIRCULATIONAHA.108.828426, 19752353.
130. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151. 10.2337/diabetes.54.1.146, 15616022.
131. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008, 146:243-249. 10.1016/j.regpep.2007.10.001, 17976835.
132. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009, 53:501-510. 10.1016/j.jacc.2008.10.033, 19195607.
133. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-983. 10.2337/db08-1193, 2661586, 19151200.
134. Kristensen J, Mortensen UM, Schmidt M, Nielsen PH, Nielsen TT, Maeng M. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord 2009, 9:31. 10.1186/1471-2261-9-31, 2728095, 19627582.
135. Sauve M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, Drucker DJ. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010, 59:1063-1073. 10.2337/db09-0955, 2844815, 20097729.
136. Ravassa S, Zudaire A, Diez J. GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res 2012, 94:316-323. 10.1093/cvr/cvs123, 22419668.
137. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350. 10.1161/CIRCULATIONAHA.107.739938, 18427132.
138. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006, 317:1106-1113. 10.1124/jpet.106.100982, 16489128.
139. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like-peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneosly hypertensive, heart failure prone rat. Circ Heart Fail 2008, 1:153-160. 10.1161/CIRCHEARTFAILURE.108.766402, 2733530, 19727407.
140. Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, Zhang R, Su T, Ma X, Zeng C, Wang H, Ren J, Cao F. Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes Via a cAMP/PKA/Rho-Dependent Mechanism. Diabetes 2013, ePub ahead of print.
141. Vyas AK, Yang KC, Woo D, Tzekov A, Kovacs A, Jay PY, Hruz PW. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One 2011, 6:e17178. 10.1371/journal.pone.0017178, 3040766, 21359201.
142. Gejl M, Sondergaard HM, Stecher C, Bibby BM, Moller N, Botker HE, Hansen SB, Gjedde A, Rungby J, Brock B. Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. J Clin Endocrinol Metab 2012, 97:E1165-E1169. 10.1210/jc.2011-3456, 22544917.
143. Kawano T, Tanaka K, Chi H, Eguchi S, Yamazaki F, Kitamura S, Kumagai N, Yokoyama M. Biophysical and pharmacological properties of glucagon-like peptide-1 in rats under isoflurane anesthesia. Anesth Analg 2012, 115:62-69. 10.1213/ANE.0b013e318253cbf0, 22504208.
144. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van HL, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation 2010, 121:586-613. 10.1161/CIRCULATIONAHA.109.192703, 20089546.
145. Hill JO, Dorton J, Sykes MN, DiGirolamo M. Reversal of dietary obesity is influenced by its duration and severity. Int J Obes 1989, 13:711-722.
146. Bartness TJ, Polk DR, McGriff WR, Youngstrom TG, DiGirolamo M. Reversal of high-fat diet-induced obesity in female rats. Am J Physiol 1992, 263:R790-R797.
147. Davidoff AJ, Mason MM, Davidson MB, Carmody MW, Hintz KK, Wold LE, Podolin DA, Ren J. Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments. Am J Physiol Endocrinol Metab 2004, 286:E718-E724. 10.1152/ajpendo.00358.2003, 15102617.
148. Llado I, Proenza AM, Serra F, Palou A, Pons A. Dietary-induced permanent changes in brown and white adipose tissue composition in rats. Int J Obes 1991, 15:415-419.
149. Szilvassy Z, Ferdinandy P, Szilvassy J, Nagy I, Karcsu S, Lonovics J, Dux L, Koltai M. The loss of pacing-induced preconditioning in atherosclerotic rabbits: role of hypercholesterolaemia. J Mol Cell Cardiol 1995, 27:2559-2569. 10.1006/jmcc.1995.0043, 8825877.
150. Shinmura K, Tamaki K, Bolli R. Short-term caloric restriction improves ischemic tolerance independent of opening of ATP-sensitive K + channels in both young and aged hearts. J Mol Cell Cardiol 2005, 39:285-296. 10.1016/j.yjmcc.2005.03.010, 15878170.
151. Hamdy O, Goodyear LJ, Horton ES. Diet and exercise in type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2001, 30:883-907. 10.1016/S0889-8529(05)70220-6, 11727404.
152. Veiga EC, Antonio EL, Bocalini DS, Murad N, Abreu LC, Tucci PJ, Sato MA. Prior exercise training does not prevent acute cardiac alterations after myocardial infarction in female rats. Clinics (Sao Paulo) 2011, 66:889-893.
153. Burelle Y, Wambolt RB, Grist M, Parsons HL, Chow JC, Antler C, Bonen A, Keller A, Dunaway GA, Popov KM, Hochachka PW, Allard MF. Regular exercise is associated with a protective metabolic phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2004, 287:H1055-H1063. 10.1152/ajpheart.00925.2003, 15105170.
154. McElroy CL, Gissen SA, Fishbein MC. Exercise-induced reduction in myocardial infarct size after coronary artery occlusion in the rat. Circulation 1978, 57:958-962. 10.1161/01.CIR.57.5.958, 639217.
155. Freimann S, Scheinowitz M, Yekutieli D, Feinberg MS, Eldar M, Kessler-Icekson G. Prior exercise training improves the outcome of acute myocardial infarction in the rat. Heart structure, function, and gene expression. J Am Coll Cardiol 2005, 45:931-938. 10.1016/j.jacc.2004.11.052, 15766831.